Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 93

Results For "sales"

1324 News Found

NATCO announces tentative approval to its ANDA for Trabectedin
Drug Approval | August 18, 2022

NATCO announces tentative approval to its ANDA for Trabectedin

According to industry sales data, Yondelis generated annual sales of $49.7 million for the twelve months ending June 2022 in the US market.


Philips CEO Frans van Houten to step down; Roy Jakobs named successor
People | August 18, 2022

Philips CEO Frans van Houten to step down; Roy Jakobs named successor

The Supervisory Board has unanimously decided to propose Roy Jakobs as the next President and CEO of Royal Philips to its General Meeting of Shareholders.


Merck and Orna Therapeutics collaborate to advance Orna’s nextgen RNA technology
Biotech | August 17, 2022

Merck and Orna Therapeutics collaborate to advance Orna’s nextgen RNA technology

Collaboration supports multiple discovery efforts, including vaccines


Lupin receives approval from U.S. FDA for Meclizine Hydrochloride Tablets USP
Drug Approval | August 16, 2022

Lupin receives approval from U.S. FDA for Meclizine Hydrochloride Tablets USP

Meclizine Hydrochloride Tablets had estimated annual sales of USD 29 million in the U.S.


ResMed Q4 revenue up 4%; operating profit up 6%
News | August 16, 2022

ResMed Q4 revenue up 4%; operating profit up 6%

The card-to-cloud device was launched into the U.S. and many other markets and is designed to work without an embedded communications module.


Lupin receives USFDA approval for Meclizine Hydrochloride Tablets USP
Drug Approval | August 13, 2022

Lupin receives USFDA approval for Meclizine Hydrochloride Tablets USP

The product will be manufactured at Lupin’s facility in Goa, India.


Congenica announces partnership with Avesthagen
Digitisation | August 13, 2022

Congenica announces partnership with Avesthagen

New deal strengthens Congenica’s presence in India


Hikal shows 17% degrowth in Q1 FY23
News | August 12, 2022

Hikal shows 17% degrowth in Q1 FY23

Pharmaceutical sales de-grew 18% YoY and stood at Rs. 224 crore whereas Crop Protection sales de-grew by 15% at Rs. 154 crore


Margin disappointment continues for Lupin in Q1FY23 : Prabhudas Lilladher
News | August 09, 2022

Margin disappointment continues for Lupin in Q1FY23 : Prabhudas Lilladher

Margins under pressure - Price erosion, shelf stock adjustments and inventory pare down in US biz impacted margins.


FDC Limited reports Q1 FY23 revenue growth of 10%
News | August 08, 2022

FDC Limited reports Q1 FY23 revenue growth of 10%

The domestic business has registered a single-digit growth on the huge base of last year and this was driven by robust demand across established therapies and brands